Literature DB >> 376355

The "treatment" of unexplained infertility with danazol.

J G van Dijk, M Frŏlich, E C Brand, E V van Hall.   

Abstract

In order to investigate the possible stimulating effect of danazol on fertility, a randomized clinical trial was performed on 40 women with unexplained infertility. Of these 40 women, 21 received 200 mg of danazol daily for 100 days and 19 received a placebo treatment during the same period. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin, estrone, estradiol, progesterone, and testosterone were followed before, during, and after treatment. Danazol administration induced anovulation in all women, with prompt resumption of normal ovulatory function after discontinuation of the drug. No influence was seen on serum LH, FSH, and testosterone levels, but serum estrone, estradiol, and progesterone levels decreased significantly during treatment. Serum prolactin levels also decreased, but not significantly. No pregnancies occurred in the placebo group during a 6-month follow-up period. In the danazol group, five pregnancies occurred, of which two were ectopic and three went to term. The difference in pregnancy rate between both groups was statistically significant (P less than 0.05).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 376355     DOI: 10.1016/s0015-0282(16)43989-0

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  Reduced expression of alphavbeta3 integrin in the endometrium of unexplained infertility patients with recurrent IVF-ET failures: improvement by danazol treatment.

Authors:  Chisei Tei; Tetsuo Maruyama; Naoaki Kuji; Toyohiko Miyazaki; Mikio Mikami; Yasunori Yoshimura
Journal:  J Assist Reprod Genet       Date:  2003-01       Impact factor: 3.412

Review 2.  Danazol in the treatment of infertility.

Authors:  R B Greenblatt
Journal:  Drugs       Date:  1980-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.